Pharmacokinetic (PK) Study of Homoharringtonine (Omacetaxine Mepesuccinate) Administered Subcutaneously to Patients With Advanced Solid and Hematologic Tumors

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Teva Pharmaceutical Industries ( ChemGenex Pharmaceuticals )
ClinicalTrials.gov Identifier:
NCT00675350
First received: May 7, 2008
Last updated: May 9, 2014
Last verified: May 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: January 2009
  Primary Completion Date: September 2008 (Final data collection date for primary outcome measure)